Supplementary Tables 1-4 from Targeting FBW7 As a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Mingxiang Ye,Yong Zhang,Xinxin Zhang,Jianbin Zhang,Pengyu Jing,Liang Cao,Nan Li,Xia Li,Libo Yao,Jian Zhang

DOI: https://doi.org/10.1158/0008-5472.22413117

2023-01-01

Abstract:This supplementary tables contain shRNAs, siRNAs, primers sequences and antibody resources.

What problem does this paper attempt to address?

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Table S1 from Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung Cancer

Yuning Liu,Qingzhe Wu,Bin Jiang,Tingting Hou,Chuanqiang Wu,Ming Wu,Hai Song

DOI: https://doi.org/10.1158/1541-7786.26144994

2024-01-01

Abstract:Supplementary Table S1. Sequences for sgRNA, shRNA or siRNA.
Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528425

2023-01-01

Abstract:PDF file, 64K, Non-small cell lung cancer cell lines.
Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528419.v1

2023-01-01

Abstract:PDF file, 53K, mRNA transcripts significantly different between SCLC and NSCLC cell lines.
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.
Supplementary Tables from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Yi Ban,Junhua Mai,Xin Li,Marisa Mitchell-Flack,Tuo Zhang,Lixing Zhang,Lotfi Chouchane,Mauro Ferrari,Haifa Shen,Xiaojing Ma

DOI: https://doi.org/10.1158/0008-5472.22412618.v1

2023-01-01

Abstract:This table contains patient clinical data and auto rejection rates of 4T1 tumors.
Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Peixiang Lu,Ge Chen,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395141

2023-01-01

Abstract:PDF file - 47K, Sequences of primers used in this study
Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964573.v1

2024-01-01

Abstract:The Supplementary Data consist of: Supplementary Tables S1-7
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Xue-Bin Ran,Ling-Wen Ding,Qiao-Yang Sun,Henry Yang,Jonathan W. Said,Lao Zhentang,Vikas Madan,Pushkar Dakle,Jin-Fen Xiao,Xinyi Loh,Ying Li,Liang Xu,Xiao-Qiang Xiang,Ling-Zhi Wang,Boon Cher Goh,De-Chen Lin,Wee Joo Chng,Soo-Yong Tan,Sudhakar Jha,H. Phillip Koeffler

DOI: https://doi.org/10.1158/0008-5472.22432644.v1

2023-01-01

Abstract:This file contains supplementary methods, Figs. S1 to S6 and Tables S1 to S5.
Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Lin Xia,Zaozao Zheng,Jun-yi Liu,Yu-jie Chen,Jiancheng Ding,Guo-sheng Hu,Ya-hong Hu,Suling Liu,Wen-xin Luo,Ning-shao Xia,Wen Liu

DOI: https://doi.org/10.1158/2326-6066.22543587

2023-01-01

Abstract:Supplementary Table 2
Supplementary Table 1 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Liang Feng,Hang-Ping Yao,Wei Wang,Yong-Qing Zhou,Jianwei Zhou,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1078-0432.22455420

2023-01-01

Abstract:Supplementary Table 1. Biochemical and biological features of anti-RON mAbs Zt/g4
Supplementary Materials, Methods and Tables from Downregulation of safb Sustains the NF-κB Pathway by Targeting tak1 During the Progression of Colorectal Cancer

Hong‐Li Jiao,Yaping Ye,Runwei Yang,Hongbin Sun,Shuyang Wang,Yongxia Wang,Zhi-Yuan Xiao,Long He,Juan‐Juan Cai,Wanzhi Wei,Yanru Chen,Chun-Cai Gu,Yue-Long Cai,Yun-Teng Hu,Qiuhua Lai,Junfeng Qiu,Liang Li,Guangwen Cao,Wenting Liao,Yan‐Qing Ding

DOI: https://doi.org/10.1158/1078-0432.22463628.v1

2023-01-01

Abstract:Supplementary materials, methods and tables
Supplementary Tables 1-3 from Targeting LUNX Inhibits Non–Small Cell Lung Cancer Growth and Metastasis

Xiaohu Zheng,Min Cheng,Binqing Fu,Xiaolei Fan,Qing Wang,Xiaoqing Yu,Rui Sun,Zhigang Tian,Haiming Wei

DOI: https://doi.org/10.1158/0008-5472.22407626

2023-01-01

Abstract:Table S1. Clinical characteristics of the cancer patients in this study. Table S2. LunX levels in 150 cases of non-small-cell lung cancer (75 lung adenocarcinoma, 75 squamous cell lung carcinoma). Table S3. The 4-year survival rate in 102 cases of non-small-cell lung cancer (NSCLC).
Supplementary Tables from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Fei Huang,Qiaoni Shi,Yuzhen Li,Linlin Xu,Chi Xu,Fenfang Chen,Hai Wang,Hongwei Liao,Zai Chang,Fang Liu,Xiang H.-F. Zhang,Xin-Hua Feng,Jing-Dong J. Han,Shiwen Luo,Ye-Guang Chen

DOI: https://doi.org/10.1158/0008-5472.22420259

2023-01-01

Abstract:Table S1 lists shRNA sequences from Sigma. Table S2 lists antibodies used in this study. Table S3 lists chemical inhibitors used in this study. Table S4 lists cell lines used in this study. Table S5 lists RT-qPCR primers and ChIP-qPCR primers used in this study
Supplemental Tables from 14-3-3σ Contributes to Radioresistance by Regulating DNA Repair and Cell Cycle Via PARP1 and CHK2

Yifan Chen,Zhaomin Li,Dong Zhao,Jenny Beebe,Ke Yang,Liwu Fu,Jian‐Ting Zhang

DOI: https://doi.org/10.1158/1541-7786.22515373.v1

2023-01-01

Abstract:Supplemental Table S1. Sequence of shRNAs and siRNAs. Supplemental Table S2. Sequences of primers for real time RT-PCR.
Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Longchuan Bai,Bing Zhou,Chao-Yie Yang,Jiao Ji,Donna McEachern,Sally Przybranowski,Hui Jiang,Jiantao Hu,Fuming Xu,Yujun Zhao,Liu Liu,Ester Fernandez-Salas,Jing Xu,Yali Dou,Bo Wen,Duxin Sun,Jennifer Meagher,Jeanne Stuckey,Daniel F. Hayes,Shunqiang Li,Matthew J. Ellis,Shaomeng Wang

DOI: https://doi.org/10.1158/0008-5472.22416456

2023-01-01

Abstract:This file include supporting tables from SI. Table 1 to Table 6.
Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression

Yongheng Chen,Ying,Wenlong Ma,Hongchao Ma,Liang Shi,Xuefeng Gao,Min Jia,Meiqi Li,Xiaoman Song,Weixiao Kong,Wei Chen,Xiangyi Zheng,Tobias Achu Muluh,Xiaobin Wang,Maolin Wang,Xing-sheng Shu

DOI: https://doi.org/10.1158/0008-5472.25603759

2024-01-01

Abstract:Target sequences of shRNAs and sgRNAs used in this study.
Supplementary Tables 1 - 3 from Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer

Yan Wang,Jian Gu,Jack A. Roth,Michelle A.T. Hildebrandt,Scott M. Lippman,Yuanqing Ye,John D. Minna,Xifeng Wu

DOI: https://doi.org/10.1158/0008-5472.22396955

2023-01-01

Abstract:PDF file - 97K, Supplementary Table S1 summarized numbers of miRNA binding sites in TGF-beta pathway-related genes; Supplementary Table S2 showed raw Ct values and normalized expression levels of 35 miRNAs for qRT-PCR assays in 383 serum samples from the NSCLC study population recruited at the University of Texas MD Anderson Cancer Center between 2002 and 2009; Supplementary Table S3 showed differentially expressed serum miRNAs between Stage III and Stage IV groups for NSCLC study population recruited at the University of Texas MD Anderson Cancer Center between 2002 and 2009.
Supplementary Table S1 from METTL1-Mediated M7g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Manling Huang,Jianting Long,Zhijia Yao,Yi Zhao,Yutong Zhao,Junbin Liao,Kai Lei,Han Xiao,Zhengde Dai,Sui Peng,Shuibin Lin,Lixia Xu,Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.22433516

2023-01-01

Abstract:This file shows the antibodies used in the study.

Supplementary Tables 1-4 from Targeting FBW7 As a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table S1 from Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung Cancer

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Tables from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Table 1 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Supplementary Materials, Methods and Tables from Downregulation of <i>safb</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>tak1</i> During the Progression of Colorectal Cancer

Supplementary Tables 1-3 from Targeting LUNX Inhibits Non–Small Cell Lung Cancer Growth and Metastasis

Supplementary Tables from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplemental Tables from 14-3-3σ Contributes to Radioresistance by Regulating DNA Repair and Cell Cycle Via PARP1 and CHK2

Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression

Supplementary Tables 1 - 3 from Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer

Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Tables 1-4 from Targeting FBW7 As a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table S1 from Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung Cancer

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Tables from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133&lt;sup&gt;+&lt;/sup&gt; Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Table 1 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Supplementary Materials, Methods and Tables from Downregulation of &lt;i&gt;safb&lt;/i&gt; Sustains the NF-&lt;b&gt;κ&lt;/b&gt;B Pathway by Targeting &lt;i&gt;tak1&lt;/i&gt; During the Progression of Colorectal Cancer

Supplementary Tables 1-3 from Targeting LUNX Inhibits Non–Small Cell Lung Cancer Growth and Metastasis

Supplementary Tables from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplemental Tables from 14-3-3σ Contributes to Radioresistance by Regulating DNA Repair and Cell Cycle Via PARP1 and CHK2

Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression

Supplementary Tables 1 - 3 from Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer

Supplementary Table S1 from METTL1-Mediated M&lt;sup&gt;7&lt;/sup&gt;g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Materials, Methods and Tables from Downregulation of <i>safb</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>tak1</i> During the Progression of Colorectal Cancer

Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma